Cellectis Announces the Final Completion of the Acquisition of Cellartis and €50 Million Financing Round Reserved for the FSI and Mr. Pierre Bastid

Regulatory News:

Not for release, publication or distribution, directly or indirectly, in Australia, Canada, Japan or the United States

Friday November 4, 2011 - Cellectis (Paris:ALCLS) announces the final completion of the acquisition of Cellartis, the Swedish company and European market leader for stem cell-based in vitro R&D tools, and the resulting issue of 1,933,333 Cellectis shares to the former Cellartis' shareholders, as well as the final completion of the issue of 6,250,000 convertible bonds for €50 million, evenly subscribed by the French strategic investment fund (FSI) and Mr. Pierre Bastid.
Consequently, the free share purchase warrants granted on November 1st, 2011 to all Cellectis' shareholders (not including the FSI, Mr. Pierre Bastid and Cellartis' shareholders) based on the Euroclear France positions at October 31st, 2011, will be registered for trading on the Alternext market of NYSE Euronext Paris on November 7th, 2011 and may be exercised from the same day until October 28th, 2014.

* * *

Disclaimer

This press release and the information contained herein do not constitute an offer to the public, an offer to subscribe, or the solicitation of the public in view of an offer of securities to the public. No offer of securities to the public will be made inside or outside France until a prospectus within the meaning of Directive 2003/71/EC is approved by the French Autorité des marchés financiers (AMF).
The distribution of this press release in certain countries may be subject to specific regulations. This press release shall not be published, released or distributed, directly or indirectly, in Australia,Canada, Japan or the United States of America. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy securities of Cellectis in Australia,Canada, Japan, the United States or any other country.
The shares, share purchase warrants, shares issuable upon exercise of the share purchase warrants, the convertible bonds and the shares issuable upon exercise of the convertible bonds of Cellectis (the "Securities"), if and when issued, may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933 as amended. The Securities have not been and will not be registered under the U.S. Securities Act and Cellectis does not intend to conduct a public offering of any of such Securities in the United States.
This press release contains forward-looking statements, including statements about Cellectis' business and prospects, its acquisition of Cellartis, and a potential offering of its Securities. Such forward-looking statements are based on data, assumptions and estimates that Cellectis considers to be reasonable. They are subject to numerous risks and uncertainties, including matters not yet known to Cellectis or not currently considered material by Cellectis, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved.Important factors that could cause actual results to differ materially from the results anticipated in forward-looking statements include, among others, the development of economic conditions, financial markets and the markets in which Cellectis operates.

Contacts:

Cellectis
Philippe Valachs
Company Secretary
Tel: [phone]
[e-mail]
or
Marc Le Bozec
Chief Financial Officer
Tel: [phone]
[e-mail]
or
Calyptus
Alexis Breton / Cyril Combe
Tel: [phone]
[e-mail]